» Articles » PMID: 32291805

Clinical Guidelines for Interstitial Cystitis/bladder Pain Syndrome

Overview
Journal Int J Urol
Specialty Urology
Date 2020 Apr 16
PMID 32291805
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical guidelines for interstitial cystitis and related symptomatic conditions were revised by updating our previous guidelines. The current guidelines define interstitial cystitis/bladder pain syndrome as a condition with chronic pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by other urinary symptoms, such as persistent urge to void or urinary frequency in the absence of confusable diseases. The characteristic symptom complex is collectively referred as hypersensitive bladder symptoms. Interstitial cystitis/bladder pain syndrome is divided into Hunner-type interstitial cystitis and bladder pain syndrome; Hunner-type interstitial cystitis and bladder pain syndrome represent interstitial cystitis/bladder pain syndrome with Hunner lesions and interstitial cystitis/bladder pain syndrome without Hunner lesions, respectively. So-called non-Hunner-type interstitial cystitis featured by glomerulations or bladder bleeding after distension is included in bladder pain syndrome. The symptoms are virtually indistinguishable between Hunner-type interstitial cystitis and bladder pain syndrome; however, Hunner-type interstitial cystitis and bladder pain syndrome should be considered as a separate entity of disorder. Histopathology totally differs between Hunner-type interstitial cystitis and bladder pain syndrome; Hunner-type interstitial cystitis is associated with severe inflammation of the urinary bladder accompanied by lymphoplasmacytic infiltration and urothelial denudation, whereas bladder pain syndrome shows little pathological changes in the bladder. Pathophysiology would also differ between Hunner-type interstitial cystitis and bladder pain syndrome, involving interaction of multiple factors, such as inflammation, autoimmunity, infection, exogenous substances, urothelial dysfunction, neural hyperactivity and extrabladder disorders. The patients should be treated differently based on the diagnosis of Hunner-type interstitial cystitis or bladder pain syndrome, which requires cystoscopy to determine the presence or absence Hunner lesions. Clinical studies are to be designed to analyze outcomes separately for Hunner-type interstitial cystitis and bladder pain syndrome.

Citing Articles

Antinociceptive properties of intravesical/needle-free administration of abobotulinumtoxinA in a rodent model of chronic visceral pain: in vivo and histological evidence.

Auge C, Vogt M, Martin V, Lezmi S, Game X, Lluel P J Neural Transm (Vienna). 2025; .

PMID: 40089646 DOI: 10.1007/s00702-025-02906-2.


Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives.

Yoshihara K, Ito K, Kimura T, Yamamoto Y, Urabe F Bladder Cancer. 2025; 11(1):23523735251322017.

PMID: 40034247 PMC: 11864234. DOI: 10.1177/23523735251322017.


Exploring the causal role of pathogen-derived antibodies in major urinary and kidney diseases: Insights from generalized summary data-based Mendelian randomization.

Huang H, Chen B, Feng C, Chen W, Wu D Virulence. 2025; 16(1):2473631.

PMID: 40033947 PMC: 11906112. DOI: 10.1080/21505594.2025.2473631.


Exploring the anti-inflammatory effects of phytochemicals in attenuating interstitial cystitis-a literature review.

Anjum I, Nasir A, Naseer F, Ibrahim A, Rehman B, Bashir F Front Pharmacol. 2025; 16:1483548.

PMID: 39974737 PMC: 11836544. DOI: 10.3389/fphar.2025.1483548.


Comorbid bladder pain syndrome and vulvodynia - a cross-sectional analysis of the UNICORN-4 study.

Okui N BMC Womens Health. 2025; 25(1):72.

PMID: 39972456 PMC: 11837444. DOI: 10.1186/s12905-025-03602-9.